Modulating the Immune System to Treat Patients with Follicular Lymphoma17 September 2018,
Publication of the results of the RELEVANCE clinical study conducted by LYSA-LYSARC, in the New England Journal of Medicine.
For patients treated at the beginning of follicular lymphoma (with a high tumor mass), RELEVANCE is the first major study comparing conventional immuno-chemotherapy treatment to a new combination of 2 drugs based on the modulation of immune system functions: lenalidomide taken orally and rituximab intravenously (also called R²).
The study was conducted in 10 countries (France, Belgium, Australia, Canada, Germany, Italy, Japan, Portugal, Spain and the United States) by the Lymphoma Study Association (LYSA) and LYSARC, in collaboration with Celgene and was published Thursday, Sept. 6 in the New England Journal of Medicine (NEJM)*.
In this study of 1030 patients (including 581 in France) with follicular lymphoma and aged at least 18 years at the time of diagnosis, half received immuno-chemotherapy, the other half had the R² combination. The treatment lasted 30 months in both arms.
After 3 years, both treatment arms show a similar efficacy, according to the treatment response rates and the identical percentage (77%) of patients in whom the disease has not progressed.
* : F Morschhauser et al., RELEVANCE : Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Versus Rituximab Plus Chemotherapy Followed by Rituximab Maintenance in Patients with Previously Untreated Follicular Lymphoma, N Engl J Med 2018 ; Sep 6 ;379(10):934-947.